
Bortetrust 2 Injection
Marketer
Panacea Biotec Pharma Ltd
Salt Composition
Bortezomib (2mg)
Overview Bortetrust 2 Injection
Bortezomib injection is indicated for treating multiple myeloma and mantle cell lymphoma. Its mechanism involves inhibiting or reducing the proliferation of cancerous cells. Administration is strictly by intravenous injection from a qualified healthcare professional. Dosage and frequency are determined by your physician, based on your specific condition and may be adjusted. Adhere precisely to your doctor's prescribed regimen; incorrect usage or overdose can lead to severe adverse effects. Therapeutic benefits might not be apparent immediately; continued use, unless advised otherwise by your doctor, is crucial. Common side effects include tiredness, nausea, vomiting, and decreased appetite. Increased daily fluid intake is often recommended. Operating machinery or driving is discouraged due to potential drowsiness and dizziness. This medication can lower blood cell counts (red and white blood cells), increasing infection risk. Regular blood tests to monitor blood cell levels, as well as heart, liver function, and uric acid are essential. Prior to commencing treatment, disclose any existing liver, kidney, heart conditions, or bleeding disorders to your doctor. Report cognitive symptoms such as memory impairment or difficulty concentrating. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception is essential for both partners throughout the treatment period.
Primary Ingredients of Bortetrust 2 Injection
No text provided to rephrase.
Uses of Bortetrust 2 Injection
Myeloma and mantle cell lymphoma
Major Benefits of Bortetrust 2 Injection:
This medication will be administered by your healthcare provider. Self-medication is not permitted.
Common Side effects of Bortetrust 2 Injection:
- Low blood platelets
- Fatigue
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Psychiatric disturbances
- Nausea
- Vomiting
- Loss of appetite
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Decreased appetite
- Decreased white blood cell count (neutrophils)
- Constipation
How to use Bortetrust 2 Injection:
Administering this medication will be done by your healthcare provider. Self-medication is strictly prohibited.
How Bortetrust 2 Injection works:
Bortezomib injection is a cancer therapy that inhibits proteasome function, hindering the degradation of cellular proteins. This accumulation of proteins within cancerous cells ultimately triggers their demise.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Bortetrust 2 Injection and alcohol may lead to significant somnolence.
PregnancyCONSULT YOUR DOCTOR
Administering Bortetrust 2 Injection during pregnancy is contraindicated due to confirmed fetal risks. Nevertheless, in exceptional, life-threatening circumstances, a physician might prescribe it when the potential advantages outweigh the hazards. Physician consultation is essential.
Breast feedingUNSAFE
Administering Bortezomib injection to breastfeeding individuals is contraindicated. Evidence indicates potential infant toxicity.
DrivingUNSAFE
Administering Bortetrust 2 Injection may induce adverse reactions impacting driving capabilities. These reactions can include fatigue, vertigo, syncope, or visual disturbances, potentially compromising safe driving.
KidneyCAUTION
For individuals with significant kidney impairment, administering Bortetrust 2 Injection requires careful consideration. Dosage modification of Bortetrust 2 Injection might be necessary. Physician consultation is advised.
LiverCAUTION
For individuals with hepatic impairment, Bortetrust 2 Injection requires careful administration. Dosage modifications for Bortetrust 2 Injection may be necessary. Physician consultation is advised.
What if you forget to take Bortetrust 2 Injection :
Omit a Bortetrust 2 Injection dose? Seek your physician's advice.
Facts to Know About Bortetrust 2 Injection
| Label | Value |
|---|---|
| Chemical Category | Phenylalanine-Based Compounds |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
